Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC
This study tests a new treatment called PSMA-UCAR T cells for men with advanced prostate cancer that no longer responds to standard treatments. The treatment involves taking immune cells from the patient's blood, modifying them in the laboratory to recognize and attack prostate cancer cells, and then returning them to the patient's body.
Key Objective:This trial is testing whether modified immune cells can safely shrink or control prostate cancer that has become resistant to conventional therapies.
Who to Consider:Men with metastatic prostate cancer that has not responded to standard treatments should consider enrolling in this study.
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a single-arm, single-center, open-label clinical trial designed to evaluate the clinical safety and tolerability of different doses of Prostate-Specific Membrane Antigen (PSMA)-Universal Chimeric Antigen Receptor (UCAR) T-lymphocytes (PSMA-UCAR T) for the treatment of patients with refractory castration-resistant prostate cancer (CRPC).
Eligibility Criteria
Inclusion Criteria: 1. Fully understood and voluntarily signed informed consent for this study; 2. Male, aged 18-80 years; 3. Expected survival of more than 6 months; 4. Metastatic castration-resistant prostate adenocarcinoma (CRPC) patients: Have received CRPC standard treatment (such as novel hormone therapies, chemotherapy and radium-223, etc., one or more of the combination therapy) after the diagnosis of CRPC, and is ineffective or progressive :PSA continued rising for 3 months, or bone scan/whole-body MRI/PET-CT showed local recurrence or new metastatic lesions, demonstrating disease progression; 5. PSMA expression in tumor cells was positive in immunohistochemical staining of prostate/metastatic biopsy tissue before enrollment (within 6 months prior to enrollment); 6. ECOG score \< 2 ; 7. Virological examination HAV (hepatitis A virus), HBV (hepatitis B virus), HCV (hepatitis C virus), HIV (human immunodeficiency virus), TP (Treponema pallidum) quantitative detection was negativ